Discussions with leaders: *JNM* editor-in-chief Johannes Czernin continues a series of interviews with leaders in nuclear and molecular imaging and therapy with a conversation with Ora Israel, highlighting her international achievements in the field. . . . . ***Page 1285***

Best practices in AI evaluation: Jha and members of an SNMMI taskforce propose a 4-class framework to evaluate artificial intelligence algorithms for potential, technical task-specific efficacy, clinical decision making, and postdeployment efficacy. . . . . ***Page 1288***

SSTR imaging in PPGL: Jha and colleagues look at the relatively limited data comparing [^{68}Ga]Ga-DOTATATE and [^{64}Cu]Cu-DOTATATE in somatostatin receptor imaging, including in patients with pheochromocytoma and paraganglioma. . . . . ***Page 1300***

Pretargeting in RIT: Cheal and colleagues provide an educational overview of the current status of radioimmunotherapy of human tumors and pretargeted radioimmunotherapy success and failure in clinical trials, including recent efforts at optimization with novel pretargeting systems. . . . . ***Page 1302***

Antibody engineering in nuclear medicine: Rodriguez and colleagues review advances in applications of antibody engineering in immunoPET, immunoSPECT, and radioimmunotherapy, with a focus on optimizing pharmacokinetics, site-specific bioconjugation, modulating Fc interactions, and creating bispecific constructs. . . . . ***Page 1316***

Radionuclide evaluation of brain death: Zuckier updates previous reporting on a widely covered case of brain death, offering additional clinical history, radionuclide image analysis, and a discussion of associated controversy and questions. . . . . ***Page 1323***

^{212}Pb-DOTAMTATE and NETs: Delpassand and colleagues present preliminary results from a phase 1 first-in-humans dose-escalation trial assessing targeted α-emitter therapy with this novel agent in patients with somatostatin receptor–positive neuroendocrine tumors. . . . . ***Page 1326***

^{18}F-rhPSMA-7.3 PET/CT in PCa staging: Langbein and colleagues detail their experience in primary prostate cancer staging with this lead compound of a new class of radiohybrid prostate-specific membrane antigen ligands. . . ***Page 1334***

PSMA PET and postprostatectomy radiation: Ng and colleagues assess the management impact of ^{18}F-DCFPyL PSMA PET/CT in patients with prostate-specific antigen (PSA) recurrence after radical prostatectomy and report on early biochemical response after radiation treatment. . . . . ***Page 1343***

^{68}Ga-PSMA CLI exposure in prostatectomy: Costa and colleagues document the occupational radiation exposure of surgical and histopathology personnel from Cerenkov luminescence imaging–guided robot-assisted radical prostatectomy in a single-injection ^{68}Ga-PSMA PET/CT CLI protocol. . . . . ***Page 1349***

Biodistribution of ^{68}Ga ligands: Klose and colleagues document organ and tumor biodistributions for various radioligand application routes in healthy mice and models of cancers expressing somatostatin receptors, prostate-specific membrane antigen, and fibroblast-activation protein. . . . . ***Page 1357***

GRPR ligands for radioligand therapy: Günther and colleagues report on basic investigations to stabilize a common ^{177}Lu gastrin-releasing peptide receptor–targeted ligand for applications in therapy of GRPR-expressing malignancies. . . . . ***Page 1364***

uPAR PET in NENs: Carlsen and colleagues report on the utility of a novel urokinase plasminogen activator receptor tracer, ^{68}Ga-NOTA-AE105, for PET assessment of uPAR expression in patients with a range of neuroendocrine neoplasms. . . . . ***Page 1371***

PET prognostic model for HNSCC: Creff and colleagues identify clinical and preoperative PET/CT parameters predicting overall survival and distant metastasis–free survival in head and neck squamous cell carcinoma patients and develop an associated prognostic model. . . . . ***Page 1378***

Exploring the immunosuppressive microenvironment: Foray and colleagues use PET/CT and PET/MRI with ^{18}F-FET and ^{18}F-DPA-714 to elucidate the role of glioma-associated microglia and macrophages in glioma initiation, monitor therapy-induced GAMM depletion, and observe GAMM repopulation. . . . . ***Page 1386***

NTR1 imaging in neuroendocrine PCa: Wu and colleagues synthesize the neurotensin receptor subtype 1–targeted tracer ^{68}Ga-DOTA-NT-20.3 and determine its affinity to androgen-dependent and -independent prostate cancer xenografts in mice. . . . . ***Page 1394***

DLL3 PET imaging in NEPC: Korsen and colleagues report on development and preclinical validation of ^{89}Zr-DFO-SC16, a delta-like ligand 3 that targets antibody SC16, for PET imaging of treatment-induced neuroendocrine prostate cancer lesions. . . . . ***Page 1401***

Short-term induced microglial depletion in stroke: Barca and colleagues investigate the effects of microglial repopulation on inflammation and functional outcomes in an ischemic mouse model using translocator protein PET/CT or PET/MRI, ex vivo characterization, and behavioral tests. . . . . ***Page 1408***

^{68}Ga-FAPI PET, CMR, and post-AMI outcomes: Diekmann and colleagues correlate fibroblast-activation protein–targeted PET results after acute myocardial infarction with tissue characteristics from cardiac MR imaging and functional outcomes. . . . . ***Page 1415***

PET segmentation in HL: Driessen and colleagues evaluate methods of lesion selection for segmentation in chronic Hodgkin lymphoma to derive metabolic tumor volume on PET and explore the influence of different methods on prognostic value, intensity, and radiomics features. . . . . ***Page 1424***

BAT activity: Erba and colleagues provide perspective on current understanding of brown adipose tissue function and imaging as a preview of an article in this issue of *JNM* on metabolic changes associated with cold activation of such tissue. . . . . ***Page 1431***

Active BAT-associated metabolic changes: Crandall and colleagues use PET/CT to assess metabolic changes associated with cold activation of brown adipose tissue in healthy adults and compare baseline blood metabolites in participants with varying amounts of active BAT. . . . . ***Page 1433***

MIRDcell V3: Katugampola and members of the SNMMI Committee on Medical Internal Radiation Dose introduce a new version of MIRDcell, a software tool for multicellular dosimetry and bioeffect modeling. . . . . ***Page 1441***

Immuno-PET/MRI of aspergillosis: Schwenck and colleagues offer an illustrated post on an *Aspergillus*-specific, ^{64}Cu-labeled tracer administered in patients with acute myeloid leukemia diagnosed with no invasive pulmonary aspergillosis or with consensus-defined IPA. . . . . ***Page 1450***